Published in Pharmacol Rev on March 01, 1987
Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol (2008) 2.36
Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol (2013) 1.83
Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother (2009) 1.83
Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol (2009) 1.51
The relative importance of CYP26A1 in hepatic clearance of all-trans retinoic acid. Biochem Pharmacol (2010) 1.00
Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. Br J Clin Pharmacol (2004) 0.90
Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. Br J Clin Pharmacol (2012) 0.87
Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. Br J Clin Pharmacol (2000) 0.87
Pharmacokinetics of tacrolimus during pregnancy. Ther Drug Monit (2012) 0.86
Spatio-temporal simulation of first pass drug perfusion in the liver. PLoS Comput Biol (2014) 0.86
Assessment of hepatic blood flow in healthy subjects by continuous infusion of indocyanine green. Br J Clin Pharmacol (1991) 0.86
Plasma binding and transport of diazepam across the blood-brain barrier. No evidence for in vivo enhanced dissociation. J Clin Invest (1989) 0.82
Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model. CPT Pharmacometrics Syst Pharmacol (2016) 0.80
Representative Sinusoids for Hepatic Four-Scale Pharmacokinetics Simulations. PLoS One (2015) 0.80
Pharmacokinetics of carumonam after single and multiple 1- and 2-g dosage regimens. Antimicrob Agents Chemother (1988) 0.80
Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies. Br J Clin Pharmacol (2014) 0.79
Lack of effect of ageing on the stereochemical disposition of propranolol. Br J Clin Pharmacol (1992) 0.77
Sandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury. J Pharm Sci (2016) 0.77
Clinical aspects of indocyanine green pharmacokinetics following portal vein administration. Br J Clin Pharmacol (1998) 0.75
Practical clinical pharmacology: drug handling and response. Br Med J (Clin Res Ed) (1988) 0.75
Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther (1975) 7.96
The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest (1975) 4.65
Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med (1981) 3.98
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem (1994) 3.75
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest (1998) 3.66
Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol (1994) 3.05
Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther (2001) 2.79
Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther (1985) 2.69
In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol (1998) 2.45
Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med (1989) 2.29
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res (1999) 2.24
Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther (1984) 2.19
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos (1999) 2.02
Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. Circulation (1999) 2.01
Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem (1985) 1.97
Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos (2000) 1.87
Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther (1996) 1.85
Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow. J Clin Invest (1974) 1.74
Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Intern Med (1976) 1.68
Effects of age and cigarette smoking on propranolol disposition. Clin Pharmacol Ther (1979) 1.62
Direct measurement of propranolol bioavailability during accumulation to steady-state. Br J Clin Pharmacol (1978) 1.60
Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol (2001) 1.59
Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination. Clin Pharmacol Ther (1979) 1.55
Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (librium). Gastroenterology (1978) 1.48
Increased toxicity and reduced clearance of lidocaine by cimetidine. Ann Intern Med (1982) 1.43
CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism. Clin Pharmacol Ther (2000) 1.42
Effects of aging and liver disease on disposition of lorazepam. Clin Pharmacol Ther (1978) 1.39
Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. J Pharmacol Exp Ther (1985) 1.38
Biological determinants of propranolol disposition in man. Clin Pharmacol Ther (1978) 1.35
Altered hepatic blood flow and drug disposition. Clin Pharmacokinet (1976) 1.34
Relation between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet aggregation in man. Clin Pharmacol Ther (1978) 1.33
Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics (1999) 1.33
Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther (1999) 1.32
Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism. Biochemistry (1984) 1.29
The influence of cirrhosis on steady-state blood concentrations of unbound propranolol after oral administration. Clin Pharmacokinet (1979) 1.28
Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. J Pharmacol Exp Ther (1987) 1.25
Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation (1987) 1.22
Normal metabolism of morphine in cirrhosis. Gastroenterology (1981) 1.22
The effect of cirrhosis on the disposition and elimination of meperidine in man. Clin Pharmacol Ther (1974) 1.22
A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther (1998) 1.21
Erythrocyte uptake and plasma binding of diphenylhydantoin. Clin Pharmacol Ther (1974) 1.21
Disposition of chlordiazepoxide: sex differences and effects of oral contraceptives. Clin Pharmacol Ther (1979) 1.16
Drug disposition and liver disease. Drug Metab Rev (1975) 1.14
P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res (1999) 1.14
Induction of propranolol metabolism by rifampicin. Br J Clin Pharmacol (1983) 1.13
Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol (1990) 1.13
Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination. J Lab Clin Med (1977) 1.13
In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics (2001) 1.12
Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res (1987) 1.12
Effects of liver disease on drug disposition in man. Biochem Pharmacol (1976) 1.11
Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res (1984) 1.11
The oral yeast flora of 10-year-old schoolchildren. Sabouraudia (1983) 1.10
The reduction of lidocaine clearance by dl-propranolol: an example of hemodynamic drug interaction. J Pharmacol Exp Ther (1973) 1.10
Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia. Clin Pharmacol Ther (1978) 1.10
Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther (1993) 1.09
An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics (1998) 1.09
Polymorphic metabolism of mephenytoin in man: pharmacokinetic interaction with a co-regulated substrate, mephobarbital. Clin Pharmacol Ther (1986) 1.08
The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects. Clin Pharmacol Ther (1990) 1.08
Effect of hypotension on liver blood flow and lidocaine disposition. N Engl J Med (1982) 1.08
Suppression of ventricular ectopic depolarizations by tocainide. Circulation (1977) 1.06
Pharmacokinetics of drug disposition: hemodynamic considerations. Annu Rev Pharmacol (1975) 1.06
Absorption metabolism and excretion of the ephedrines in man. I. The influence of urinary pH and urine volume output. J Pharmacol Exp Ther (1968) 1.05
A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther (1999) 1.05
Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther (1989) 1.05
Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. J Pharmacol Exp Ther (1999) 1.04
Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther (1994) 1.03
Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone. Cancer Epidemiol Biomarkers Prev (1999) 1.03
Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma. AIDS Res Hum Retroviruses (2000) 1.02
Influence of genetic polymorphism on the metabolism and disposition of encainide in man. J Pharmacol Exp Ther (1984) 1.02
Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6. Clin Pharmacol Ther (1998) 1.01
Human liver microsomal N-hydroxylation of dapsone by cytochrome P-4503A4. Mol Pharmacol (1992) 1.01
Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J Pharmacol Exp Ther (1977) 1.01
Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus. Arthritis Rheum (1986) 0.99
Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J Pharmacol Exp Ther (1987) 0.98
Bupivacaine levels in plasma and cerebrospinal fluid following peridural administration. Anesthesiology (1970) 0.97
Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation. J Pharmacol Exp Ther (1988) 0.96
Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquin, and mephenytoin. Clin Pharmacol Ther (1990) 0.96
Plasma binding of benzodiazepines in humans. J Pharm Sci (1979) 0.95
Interaction of quinidine with anticonvulsant drugs. N Engl J Med (1976) 0.95
Perfusion-limited of plasma drug binding on hepatic drug extraction. Life Sci (1976) 0.94
Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent. Br J Clin Pharmacol (1999) 0.94
Differences in plasma binding of drugs between Caucasians and Chinese subjects. Clin Pharmacol Ther (1990) 0.94
Drug metabolites in renal failure: pharmacokinetic and clinical implications. Clin Pharmacokinet (1982) 0.93
Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals. J Clin Invest (1984) 0.93
Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man. Drug Metab Dispos (1987) 0.93
Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockade. Clin Pharmacol Ther (1984) 0.93
Meperidine disposition in man: influence of urinary pH and route of administration. Clin Pharmacol Ther (1981) 0.92
Abnormal regulation of plasma pyridoxal 5'-phosphate in patients with liver disease. Gastroenterology (1976) 0.92
Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine. Br J Clin Pharmacol (1989) 0.92
Effect of heparin administration on plasma binding of benzodiazepines. Br J Clin Pharmacol (1980) 0.91
In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. J Pharmacol Exp Ther (1996) 0.90
Brain uptake of benzodiazepines: effects of lipophilicity and plasma protein binding. J Pharmacol Exp Ther (1988) 0.90
Effects of alteration of hepatic microsomal enzyme activity on liver blood flow in the rat. Biochem Pharmacol (1976) 0.90
Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. Clin Pharmacol Ther (1986) 0.90
Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. Am J Cardiol (1980) 0.90
S-mephenytoin 4-hydroxylase is inherited as an autosomal-recessive trait in Japanese families. Clin Pharmacol Ther (1987) 0.89
Antiarrhythmic effects of a lidocaine congener, tocainide, 2-amino-2',6'-propionoxylidide, in man. Clin Pharmacol Ther (1976) 0.89
The influence of indomethacin on the pharmacokinetics, diuretic response and hemodynamics of furosemide in the dog. J Pharmacol Exp Ther (1978) 0.88
Absorption, metabolism, and excretion of the ephedrines in man. II. Pharmacokinetics. J Pharm Sci (1968) 0.88
Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography. J Chromatogr (1984) 0.88